• FreeWill

  Led · Series B · Mar 2022

  FreeWill offers free online tools that help Americans create wills, plan estates, and make tax-advantaged charitable donations. The company’s product suite includes a Bequest Tool for legacy giving, a Qualified Charitable Distributions Tool, a Stock Gifts Tool, and a Crypto for Charity tool to enable nonprofits to accept crypto donations. FreeWill partners with more than 1,000 nonprofits to provide estate-planning and related tools at no cost to consumers. To date the platform has generated nearly $5 billion in planned and real-time gifts for over 10,000 nonprofits and helped more than 460,000 consumers create wills and plan their estates. Led by CEOs Jenny Xia Spradling and Patrick Schmitt, the company is expanding capabilities to accept a wider range of non-cash gifts. The company plans to use new funding to accelerate growth and product development and to scale its nonprofit support capabilities.

• HiMama

  Led · Equity · Nov 2021

  HiMama is a Certified B Corporation that provides childcare centers with software to manage staff and class scheduling, tuition billing and payments, classroom learning activities, and parent engagement to improve educational outcomes for young children. The company’s platform is used in over 10,000 childcare centers across Canada and the U.S. and has enabled communication with more than one million parents. HiMama is led by CEO Ron Spreeuwenberg and CTO Alana Frome and is based in Toronto and Boston. The company acquired FunShine Express in June 2021 to offer comprehensive curriculum and activity planning. HiMama intends to use new funding to expand operations and accelerate growth. HiMama provides a software solution for child care programs to plan lessons, document children's development, share updates with families, and accept tuition payments. The platform is used in thousands of child care centers globally and has captured more than 400 million moments to date. Co‑founded by CEO Ron Spreeuwenberg and CTO Alana Frome, the company is a Certified B Corporation. HiMama intends to use its recent funding to expand its childcare software offering. The product improves center operations while keeping parents connected with their children. The company is based in Toronto, Canada.

• PresenceLearning

  Led · Series D · May 2020

  PresenceLearning offers a proprietary online platform that connects speech-language pathologists, occupational therapists, and behavioral and mental health professionals with K-12 students. The company has delivered more than 2.5 million teletherapy sessions through its network of over 1,000 certified clinicians. Its services are used by hundreds of K-12 schools and districts across the U.S. PresenceLearning was founded in 2009 and is led by CEO Kate Eberle Walker. The company intends to use new funding to accelerate expansion of its online therapy and assessment services. The platform focuses on delivering remote special-education related services to school systems. PresenceLearning is a telehealth platform and marketplace that connects clinicians with K-12 students for live speech therapy, occupational therapy, behavioral and mental health services. Founded in 2009, the company operates a nationwide network of online professionals that includes hundreds of speech language pathologists, occupational therapists, special education teachers, and behavioral and mental health providers. PresenceLearning delivers live interactive video sessions with progress reporting and says it benefits tens of thousands of children every day. The company plans to continue growing within K-12 services while expanding into additional allied health fields and new user populations, including hospitals and other care settings. Its stated mission is to make online therapy practical, affordable, and convenient for broader patient populations. PresenceLearning provides K-12 schools with access to a nationwide network of qualified, fully licensed clinicians, including speech-language pathologists, counselors, and occupational therapists. Students access these professionals via live videoconferencing while parents and teachers receive reports and analytics on the child’s progress. Founded in 2009, the company has more than doubled its student base each of the past three years and recently completed its 200,000th live online therapy session. PresenceLearning reports that students served by its therapists consistently exceed national benchmarks for clinical progress, beating averages on common language goals by roughly 13 percentage points. The company positions its offering as a way to increase clinical efficiency and lower costs for schools, noting special education represents about 13% of students and 20% of K-12 spending—roughly 7 million students and at least $60 billion in annual spend. These product capabilities and metrics underscore the company’s traction within the special-education market.

• SpringWorks Therapeutics

  Participated · Series A · Sep 2017

  SpringWorks Therapeutics is a precision-medicine biotech focused on targeted oncology programs led by nirogacestat, a gamma secretase inhibitor being developed as a potentiator of BCMA-targeted therapies. The company is studying nirogacestat in combination with GSK’s anti-BCMA ADC Blenrep in relapsed/refractory multiple myeloma, exploring use in earlier lines of therapy, and testing combinations with BCMA bispecific antibodies and CAR-T therapies from AbbVie and Pfizer. Its pipeline also includes the MEK inhibitor mirdametinib and a RAF fusion/dimer inhibitor, BGB-3245. SpringWorks expects its first drug launches next year and continues to advance a diversified clinical pipeline. Financially, the company announced a $225 million financing and a separate $75 million equity investment tied to an expanded collaboration with GSK. GSK will continue to fund most development costs and has pledged up to $550 million in additional milestone payments to support further studies and potential commercialization of the combination. SpringWorks Therapeutics is a clinical-stage biopharmaceutical company launched in 2017 that focuses on therapies for severe rare diseases and targeted oncology. Its lead development programs include nirogacestat, a gamma secretase inhibitor for desmoid tumors, and PD-0325901, a MEK 1/2 inhibitor for neurofibromatosis type 1-associated plexiform neurofibromas. PD-0325901 is also described as a potential backbone for combination therapies to treat metastatic solid tumors. The company began with licensed clinical therapies from Pfizer and leverages partnerships with patient groups, industry and academia. SpringWorks plans to advance its two late-stage programs toward potential regulatory approval and commercialization and expects two therapies to enter potentially pivotal studies in the first half of 2019. The $125 million Series B financing will support those programs, expansion of emerging targeted oncology programs, and future in-licensing and clinical collaborations. SpringWorks Therapeutics launched with rights to four clinical-stage experimental therapies from Pfizer and a stated focus on diseases with high unmet need. The company plans Phase 3 programs for nirogacestat (PF-03084014) in desmoid tumor and for the MEK 1/2 inhibitor PD-0325901 in NF1, and intends to assess senicapoc (PF-05416266) for hereditary xerocytosis and PF-0445784 (a FAAH inhibitor) for PTSD. SpringWorks says it will expand its pipeline by partnering with other life science companies and academic institutions and will work collaboratively with patient organizations such as the Desmoid Tumor Research Foundation, the Children’s Tumor Foundation, and Cohen Veterans Bioscience. Pfizer contributed both equity capital and royalty- and milestone-bearing licenses to the experimental therapies as part of the arrangement. The company emphasizes a collaborative business model designed to deliver both social and financial returns via partnerships with scientists, biopharma partners, patient groups, funders and philanthropists. The organization is led by industry veterans including Founder and President Lara S. Sullivan; the announcement was datelined New York.

No current team members are available.